Metabolic aspects of adult patients with nonalcoholic fatty liver disease

World Journal of Gastroenterology

Volumn 22, Issue 31, 2016, Pages 7006-7016

  Abenavoli, Ludovico ^a   Milic, Natasa ^b   Di Renzo, Laura ^c   Preveden, Tomislav ^b   Medic Stojanoska, Milica ^b   De Lorenzo, Antonino ^c  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF NOVI SAD   (Serbia)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; APELIN; CHEMERIN; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; LYSOPHOSPHOLIPASE; NEUROCAN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESTATIN; PHOSPHOPROTEIN PHOSPHATASE 1; RESISTIN; RETINOL BINDING PROTEIN 4; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN;

ADIPOSE TISSUE; BACTERIAL COLONIZATION; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CYTOKINE PRODUCTION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DOWN REGULATION; DYSBIOSIS; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GLUCONEOGENESIS; HUMAN; HYPERCORTISOLISM; INSULIN RESISTANCE; INTESTINE FLORA; LIPID STORAGE; LIPOGENESIS; LIVER CELL; METABOLIC PARAMETERS; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN POLYMORPHISM; PROTEIN SECRETION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; VITAMIN D DEFICIENCY; ADULT; BLOOD; COMPLICATION; LIPID METABOLISM; LIVER; METABOLISM;

ADIPONECTIN; ADULT; DYSBIOSIS; HUMANS; INSULIN RESISTANCE; INTERLEUKIN-6; LIPID METABOLISM; LIVER; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; VITAMIN D DEFICIENCY;

EID: 84982106401     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i31.7006     Document Type: Review

References (96)

1. Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis 1986; 8: 283-298 [PMID: 3086934]
2. Masarone M, Federico A, Abenavoli L, Loguercio C, Persico M. Non alcoholic fatty liver: epidemiology and natural history. Rev Recent Clin Trials 2014; 9: 126-133 [PMID: 25514916 DOI: 10.217 4/1574887109666141216111143]
3. Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. Clin Liver Dis 2016; 20: 205-214 [PMID: 27063264 DOI: 10.1016/j.cld.2015.10.001]
4. Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis 2009; 41: 615-625 [PMID: 19223251 DOI: 10.1016/j.dld.2009.01.004]
5. Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, Lonardo A. From NAFLD in clinical practice to answers from guidelines. J Hepatol 2013; 59: 859-871 [PMID: 23751754 DOI: 10.1016/j.jhep.2013.05.044]
6. Tarantino G, Finelli C. What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome? World J Gastroenterol 2013; 19: 3375-3384 [PMID: 23801829 DOI: 10.3748/wjg.v19.i22.3375]
7. European Association for the Study of the Liver (EASL). Electronic address: easloffice@easloffice.eu; European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388-1402 [PMID: 27062661 DOI: 10.1016/j.jhep.2015.11.004]
8. Almeda-Valdes P, Aguilar-Olivos N, Uribe M, Méndez-Sánchez N. Common features of the metabolic syndrome and nonalcoholic fatty liver disease. Rev Recent Clin Trials 2014; 9: 148-158 [PMID: 25514910 DOI: 10.2174/1574887109666141216103908]
9. Machado MV, Cortez-Pinto H. Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet. Int J Mol Sci 2016; 17: 481 [PMID: 27043550 DOI: 10.3390/ijms17040481]
10. Younossi ZM, Henry L. Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease. Pharmacoeconomics 2015; 33: 1245-1253 [PMID: 26233836 DOI: 10.1007/s40273-015-0316-5]
11. Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 2013; 5: 1544-1560 [PMID: 23666091 DOI: 10.3390/nu5051544]
12. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015; 62: S47-S64 [PMID: 25920090 DOI: 10.1016/j.jhep.2014.12.012]
13. Berk PD, Verna EC. Nonalcoholic Fatty Liver Disease: Lipids and Insulin Resistance. Clin Liver Dis 2016; 20: 245-262 [PMID: 27063267 DOI: 10.1016/j.cld.2015.10.007]
14. Gambino R, Bugianesi E, Rosso C, Mezzabotta L, Pinach S, Alemanno N, Saba F, Cassader M. Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load. Int J Mol Sci 2016; 17: 479 [PMID: 27043543 DOI: 10.3390/ijms17040479]
15. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-845 [PMID: 9547102]
16. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52: 1836-1846 [PMID: 21038418 DOI: 10.1002/hep.24001]
17. Abenavoli L, Milic N, Peta V, Alfieri F, De Lorenzo A, Bellentani S. Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet. World J Gastroenterol 2014; 20: 16831-16840 [PMID: 25492997 DOI: 10.3748/wjg.v20.i45.16831]
18. Walle P, Takkunen M, Männistö V, Vaittinen M, Lankinen M, Kärjä V, Käkelä P, Ågren J, Tiainen M, Schwab U, Kuusisto J, Laakso M, Pihlajamäki J. Fatty acid metabolism is altered in non-alcoholic steatohepatitis independent of obesity. Metabolism 2016; 65: 655-666 [PMID: 27085774 DOI: 10.1016/j.metabol.2016.01.011]
19. Barbarroja N, Lopez-Pedrera C, Garrido-Sanchez L, Mayas MD, Oliva-Olivera W, Bernal-Lopez MR, El Bekay R, Tinahones FJ. Progression from high insulin resistance to type 2 diabetes does not entail additional visceral adipose tissue inflammation. PLoS One 2012; 7: e48155 [PMID: 23110196 DOI: 10.1371/journal. pone.0048155]
20. Abenavoli L, Bellentani S. Milk thistle to treat non-alcoholic fatty liver disease: dream or reality? Expert Rev Gastroenterol Hepatol 2013; 7: 677-679 [PMID: 24134155 DOI: 10.1586/17474124.2013. 842893]
21. Povero D, Feldstein AE. Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis. Diabetes Metab J 2016; 40: 1-11 [PMID: 26912150 DOI: 10.4093/dmj.2016.40.1.1]
22. Macaluso FS, Maida M, Petta S. Genetic background in nonalcoholic fatty liver disease: A comprehensive review. World J Gastroenterol 2015; 21: 11088-11111 [PMID: 26494964 DOI: 10.3748/wjg.v21.i39.11088]
23. Dongiovanni P, Romeo S, Valenti L. Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis. Biomed Res Int 2015; 2015: 460190 [PMID: 26273621 DOI: 10.1155/2015/460190]
24. Kalia HS, Gaglio PJ. The Prevalence and Pathobiology of Nonalcoholic Fatty Liver Disease in Patients of Different Races or Ethnicities. Clin Liver Dis 2016; 20: 215-224 [PMID: 27063265 DOI: 10.1016/j.cld.2015.10.005]
25. Xia MF, Ling Y, Bian H, Lin HD, Yan HM, Chang XX, Li XM, Ma H, Wang D, Zhang LS, Wang SS, Wu BJ, He WY, Zhao NQ, Gao X. I148M variant of PNPLA3 increases the susceptibility to non-alcoholic fatty liver disease caused by obesity and metabolic disorders. Aliment Pharmacol Ther 2016; 43: 631-642 [PMID: 26765961 DOI: 10.1111/apt.13521]
26. Chen LZ, Hua-Xiang Xia H, Xin YN, Lin ZH, Xuan SY. TM6SF2 E167K Variant, a Novel Genetic Susceptibility Variant, Contributing to Nonalcoholic Fatty Liver Disease. J Clin Transl Hepatol 2015; 3: 265-270 [PMID: 26807382 DOI: 10.14218/JCTH.2015.00023]
27. Tan HL, Mohamed R, Mohamed Z, Zain SM. Phosphatidy-lethanolamine N-methyltransferase gene rs7946 polymorphism plays a role in risk of nonalcoholic fatty liver disease: evidence from meta-analysis. Pharmacogenet Genomics 2016; 26: 88-95 [PMID: 26636496 DOI: 10.1097/FPC.0000000000000193]
28. Lin YC, Chang PF, Chang MH, Ni YH. Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals. Am J Clin Nutr 2014; 99: 869-874 [PMID: 24477042 DOI: 10.3945/ajcn.113.079749]
29. Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update. Physiol Rev 2013; 93: 359-404 [PMID: 23303913 DOI: 10.1152/physrev.00033.2011]
30. Stojsavljevic S, Gomercic Palcic M, Virovic Jukic L, Smircic Duvnjak L, Duvnjak M. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20: 18070-18091 [PMID: 25561778 DOI: 10.3748/wjg.v20.i48.18070]
31. Bekaert M, Verhelst X, Geerts A, Lapauw B, Calders P. Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: a systematic review. Obes Rev 2016; 17: 68-80 [PMID: 26597657 DOI: 10.1111/obr.12333]
32. Abenavoli L, Peta V. Role of adipokines and cytokines in nonalcoholic fatty liver disease. Rev Recent Clin Trials 2014; 9: 134-140 [PMID: 25514909 DOI: 10.2174/1574887109666141216102458]
33. Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism 2016; 65: 1062-1079 [PMID: 26725002 DOI: 10.1016/j.metabol.2015.11.006]
34. Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, Ebenbichler CF, Patsch JR, Tilg H. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005; 54: 117-121 [PMID: 15591515 DOI: 10.1136/gut.2003.037010]
35. Heiker JT, Kosel D, Beck-Sickinger AG. Molecular mechanisms of signal transduction via adiponectin and adiponectin receptors. Biol Chem 2010; 391: 1005-1018 [PMID: 20536390 DOI: 10.1515/BC.2010.104]
36. Medina-Urrutia A, Posadas-Romero C, Posadas-Sánchez R, Jorge-Galarza E, Villarreal-Molina T, González-Salazar Mdel C, Cardoso-Saldaña G, Vargas-Alarcón G, Torres-Tamayo M, Juárez-Rojas JG. Role of adiponectin and free fatty acids on the association between abdominal visceral fat and insulin resistance. Cardiovasc Diabetol 2015; 14: 20 [PMID: 25849597 DOI: 10.1186/s12933-015-0184-5]
37. Park PH, Sanz-Garcia C, Nagy LE. Adiponectin as an anti-fibrotic and anti-inflammatory adipokine in the liver. Curr Pathobiol Rep 2015; 3: 243-252 [PMID: 26858914]
38. Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 2011; 60: 313-326 [PMID: 21040935 DOI: 10.1016/j.metabol.2010.09.003]
39. van der Poorten D, Samer CF, Ramezani-Moghadam M, Coulter S, Kacevska M, Schrijnders D, Wu LE, McLeod D, Bugianesi E, Komuta M, Roskams T, Liddle C, Hebbard L, George J. Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause? Hepatology 2013; 57: 2180-2188 [PMID: 22996622 DOI: 10.1002/hep.26072]
40. Younossi ZM, Jarrar M, Nugent C, Randhawa M, Afendy M, Stepanova M, Rafiq N, Goodman Z, Chandhoke V, Baranova A. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 2008; 18: 1430-1437 [PMID: 18500507 DOI: 10.1007/s11695-008-9506-y]
41. Coppari R, Bjørbæk C. Leptin revisited: its mechanism of action and potential for treating diabetes. Nat Rev Drug Discov 2012; 11: 692-708 [PMID: 22935803 DOI: 10.1038/nrd3757]
42. Meek TH, Morton GJ. The role of leptin in diabetes: metabolic effects. Diabetologia 2016; 59: 928-932 [PMID: 26969486 DOI: 10.1007/s00125-016-3898-3]
43. Polyzos SA, Aronis KN, Kountouras J, Raptis DD, Vasiloglou MF, Mantzoros CS. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia 2016; 59: 30-43 [PMID: 26407715 DOI: 10.1007/s00125-015-3769-3]
44. López-Jaramillo P, Gómez-Arbeláez D, López-López J, López-López C, Martínez-Ortega J, Gómez-Rodríguez A, Triana-Cubillos S. The role of leptin/adiponectin ratio in metabolic syndrome and diabetes. Horm Mol Biol Clin Investig 2014; 18: 37-45 [PMID: 25389999 DOI: 10.1515/hmbci-2013-0053]
45. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005; 174: 5789-5795 [PMID: 15843582 DOI: 10.4049/jimmunol.174.9.5789]
46. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312 [PMID: 11201732 DOI: 10.1038/35053000]
47. Kang YE, Kim JM, Joung KH, Lee JH, You BR, Choi MJ, Ryu MJ, Ko YB, Lee MA, Lee J, Ku BJ, Shong M, Lee KH, Kim HJ. The Roles of Adipokines, Proinflammatory Cytokines, and Adipose Tissue Macrophages in Obesity-Associated Insulin Resistance in Modest Obesity and Early Metabolic Dysfunction. PLoS One 2016; 11: e0154003 [PMID: 27101398 DOI: 10.1371/journal. pone.0154003]
48. Shen C, Zhao CY, Wang W, Wang YD, Sun H, Cao W, Yu WY, Zhang L, Ji R, Li M, Gao J. The relationship between hepatic resistin overexpression and inflammation in patients with nonalcoholic steatohepatitis. BMC Gastroenterol 2014; 14: 39 [PMID: 24559185 DOI: 10.1186/1471-230X-14-39]
49. Valenti L, Fracanzani AL, Dongiovanni P, Santorelli G, Branchi A, Taioli E, Fiorelli G, Fargion S. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 274-280 [PMID: 11832442 DOI: 10.1053/gast.2002.31065]
50. Wang JK, Feng ZW, Li YC, Li Q Y, Tao XY. Association of tumor necrosis factor-α gene promoter polymorphism at sites-308 and-238 with non-alcoholic fatty liver disease: a meta-analysis. J Gastroenterol Hepatol 2012; 27: 670-676 [PMID: 22097889 DOI: 10.1111/j.1440-1746.2011.06978.x]
51. Cheng Y, An B, Jiang M, Xin Y, Xuan S. Association of Tumor Necrosis Factor-alpha Polymorphisms and Risk of Coronary Artery Disease in Patients With Non-alcoholic Fatty Liver Disease. Hepat Mon 2015; 15: e26818 [PMID: 25825591 DOI: 10.5812/hepatmon.26818]
52. Tilg H. The role of cytokines in non-alcoholic fatty liver disease. Dig Dis 2010; 28: 179-185 [PMID: 20460908 DOI: 10.1159/000282083]
53. Wolf J, Rose-John S, Garbers C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine 2014; 70: 11-20 [PMID: 24986424 DOI: 10.1016/j.cyto.2014.05.024]
54. Tarantino G, Conca P, Pasanisi F, Ariello M, Mastrolia M, Arena A, Tarantino M, Scopacasa F, Vecchione R. Could inflammatory markers help diagnose nonalcoholic steatohepatitis? Eur J Gastroenterol Hepatol 2009; 21: 504-511 [PMID: 19318968 DOI: 10.1097/MEG.0b013e3283229b40]
55. Grigorescu M, Crisan D, Radu C, Grigorescu MD, Sparchez Z, Serban A. A novel pathophysiological-based panel of biomarkers for the diagnosis of nonalcoholic steatohepatitis. J Physiol Pharmacol 2012; 63: 347-353 [PMID: 23070083]
56. Jamali R, Arj A, Razavizade M, Aarabi MH. Prediction of Nonalcoholic Fatty Liver Disease Via a Novel Panel of Serum Adipokines. Medicine (Baltimore) 2016; 95: e2630 [PMID: 26844476 DOI: 10.1097/MD.0000000000002630]
57. Genc H, Dogru T, Kara M, Tapan S, Ercin CN, Acikel C, Karslioglu Y, Bagci S. Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease. Ann Hepatol 2013; 12: 548-555 [PMID: 23813132]
58. Ercin CN, Dogru T, Tapan S, Kara M, Haymana C, Karadurmus N, Karslioglu Y, Acikel C. Plasma apelin levels in subjects with nonalcoholic fatty liver disease. Metabolism 2010; 59: 977-981 [PMID: 20045153 DOI: 10.1016/j.metabol.2009.10.019]
59. Estep M, Abawi M, Jarrar M, Wang L, Stepanova M, Elariny H, Moazez A, Goodman Z, Chandhoke V, Baranova A, Younossi ZM. Association of obestatin, ghrelin, and inflammatory cytokines in obese patients with non-alcoholic fatty liver disease. Obes Surg 2011; 21: 1750-1757 [PMID: 21744131 DOI: 10.1007/s11695-011-0475-1]
60. Chang X, Yan H, Bian H, Xia M, Zhang L, Gao J, Gao X. Serum retinol binding protein 4 is associated with visceral fat in human with nonalcoholic fatty liver disease without known diabetes: a cross-sectional study. Lipids Health Dis 2015; 14: 28 [PMID: 25890223 DOI: 10.1186/s12944-015-0033-2]
61. Hatziagelaki E, Herder C, Tsiavou A, Teichert T, Chounta A, Nowotny P, Pacini G, Dimitriadis G, Roden M. Serum Chemerin Concentrations Associate with Beta-Cell Function, but Not with Insulin Resistance in Individuals with Non-Alcoholic Fatty Liver Disease (NAFLD). PLoS One 2015; 10: e0124935 [PMID: 25933030 DOI: 10.1371/journal.pone.0124935]
62. Fotbolcu H, Zorlu E. Nonalcoholic fatty liver disease as a multi-systemic disease. World J Gastroenterol 2016; 22: 4079-4090 [PMID: 27122660 DOI: 10.3748/wjg.v22.i16.4079]
63. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421 [PMID: 12485966]
64. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005; 42: 987-1000 [PMID: 16250043 DOI: 10.1002/hep.20920]
65. Motamed N, Sohrabi M, Ajdarkosh H, Hemmasi G, Maadi M, Sayeedian FS, Pirzad R, Abedi K, Aghapour S, Fallahnezhad M, Zamani F. Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease. World J Gastroenterol 2016; 22: 3023-3030 [PMID: 26973398 DOI: 10.3748/wjg.v22.i10.3023]
66. Abenavoli L, DI Renzo L, Guzzi PH, Pellicano R, Milic N, DE Lorenzo A. Non-alcoholic fatty liver disease severity, central fat mass and adinopectin: a close relationship. Clujul Med 2015; 88: 489-493 [PMID: 26733747 DOI: 10.15386/cjmed-595]
67. Walker GE, Marzullo P, Ricotti R, Bona G, Prodam F. The pathophysiology of abdominal adipose tissue depots in health and disease. Horm Mol Biol Clin Investig 2014; 19: 57-74 [PMID: 25390016 DOI: 10.1515/hmbci-2014-0023]
68. Abenavoli L, Luigiano C, Guzzi PH, Milic N, Morace C, Stelitano L, Consolo P, Miraglia S, Fagoonee S, Virgilio C, Luzza F, De Lorenzo A, Pellicano R. Serum adipokine levels in overweight patients and their relationship with non-alcoholic fatty liver disease. Panminerva Med 2014; 56: 189-193 [PMID: 24994581]
69. Byrne CD, Targher G. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. Arterioscler Thromb Vasc Biol 2014; 34: 1155-1161 [PMID: 24743428 DOI: 10.1161/ATVBAHA.114.303034]
70. Smith U. Abdominal obesity: a marker of ectopic fat accumulation. J Clin Invest 2015; 125: 1790-1792 [PMID: 25932676 DOI: 10.1172/JCI81507]
71. Byrne CD. Ectopic fat, insulin resistance and non-alcoholic fatty liver disease. Proc Nutr Soc 2013; 72: 412-419 [PMID: 23668723 DOI: 10.1017/S0029665113001249]
72. Vollenweider P, von Eckardstein A, Widmann C. HDLs, diabetes, and metabolic syndrome. Handb Exp Pharmacol 2015; 224: 405-421 [PMID: 25522996 DOI: 10.1007/978-3-319-09665-0-12]
73. Ponziani FR, Pecere S, Gasbarrini A, Ojetti V. Physiology and pathophysiology of liver lipid metabolism. Expert Rev Gastroenterol Hepatol 2015; 9: 1055-1067 [PMID: 26070860 DOI: 10.1586/17474 124.2015.1056156]
74. Cohen DE, Fisher EA. Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease. Semin Liver Dis 2013; 33: 380-388 [PMID: 24222095 DOI: 10.1055/s-0033-1358519]
75. Kluwe J, Pradere JP, Gwak G Y, Mencin A, De Minicis S, Osterreicher CH, Colmenero J, Bataller R, Schwabe RF. Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology 2010; 138: 347-359 [PMID: 19782079 DOI: 10.1053/j.gastro.2009.09.015]
76. Croci I, Byrne NM, Choquette S, Hills AP, Chachay VS, Clouston AD, O'Moore-Sullivan TM, Macdonald GA, Prins JB, Hickman IJ. Whole-body substrate metabolism is associated with disease severity in patients with non-alcoholic fatty liver disease. Gut 2013; 62: 1625-1633 [PMID: 23077135 DOI: 10.1136/gutjnl-2012-302789]
77. Abenavoli L, Scarpellini E, Rouabhia S, Balsano C, Luzza F. Probiotics in non-alcoholic fatty liver disease: which and when. Ann Hepatol 2013; 12: 357-363 [PMID: 23619251]
78. Abdou RM, Zhu L, Baker RD, Baker SS. Gut Microbiota of Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2016; 61: 1268-1281 [PMID: 26898658 DOI: 10.1007/s10620-016-4045-1]
79. He X, Ji G, Jia W, Li H. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Application of Metabolomics. Int J Mol Sci 2016; 17: 300 [PMID: 26999104 DOI: 10.3390/ijms17030300]
80. Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology 2014; 146: 1513-1524 [PMID: 24440671 DOI: 10.1053/j.gastro.2014.01.020]
81. Houghton D, Stewart CJ, Day CP, Trenell M. Gut Microbiota and Lifestyle Interventions in NAFLD. Int J Mol Sci 2016; 17: 447 [PMID: 27023533 DOI: 10.3390/ijms17040447]
82. Wieland A, Frank DN, Harnke B, Bambha K. Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2015; 42: 1051-1063 [PMID: 26304302 DOI: 10.1111/apt.13376]
83. Ritze Y, Bárdos G, Claus A, Ehrmann V, Bergheim I, Schwiertz A, Bischoff SC. Lactobacillus rhamnosus GG protects against nonalcoholic fatty liver disease in mice. PLoS One 2014; 9: e80169 [PMID: 24475018 DOI: 10.1371/journal.pone.0080169]
84. Raman M, Ahmed I, Gillevet PM, Probert CS, Ratcliffe NM, Smith S, Greenwood R, Sikaroodi M, Lam V, Crotty P, Bailey J, Myers RP, Rioux KP. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2013; 11: 868-875.e1-3 [PMID: 23454028 DOI: 10.1016/j.cgh.2013.02.015]
85. Chung GE, Kim D, Kwak MS, Yang JI, Yim JY, Lim SH, Itani M. The serum vitamin D level is inversely correlated with nonalcoholic fatty liver disease. Clin Mol Hepatol 2016; 22: 146-151 [PMID: 27044765 DOI: 10.3350/cmh.2016.22.1.146]
86. Abenavoli L, Milic N, Luigiano C. Low 25-hydroxyvitamin D3 serum levels and non-alcoholic fatty liver disease. Minerva Med 2014; 105: 175 [PMID: 24727882]
87. Eliades M, Spyrou E. Vitamin D: a new player in non-alcoholic fatty liver disease? World J Gastroenterol 2015; 21: 1718-1727 [PMID: 25684936 DOI: 10.3748/wjg.v21.i6.1718]
88. George PS, Pearson ER, Witham MD. Effect of vitamin D supplementation on glycaemic control and insulin resistance: a systematic review and meta-analysis. Diabet Med 2012; 29: e142-e150 [PMID: 22486204 DOI: 10.1111/j.1464-5491.2012.03672.x]
89. Eliades M, Spyrou E, Agrawal N, Lazo M, Brancati FL, Potter JJ, Koteish AA, Clark JM, Guallar E, Hernaez R. Meta-analysis: vitamin D and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2013; 38: 246-254 [PMID: 23786213 DOI: 10.1111/apt.12377]
90. Barchetta I, Carotti S, Labbadia G, Gentilucci U V, Muda AO, Angelico F, Silecchia G, Leonetti F, Fraioli A, Picardi A, Morini S, Cavallo MG. Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. Hepatology 2012; 56: 2180-2187 [PMID: 22753133 DOI: 10.1002/hep.25930]
91. Bril F, Maximos M, Portillo-Sanchez P, Biernacki D, Lomonaco R, Subbarayan S, Correa M, Lo M, Suman A, Cusi K. Relationship of vitamin D with insulin resistance and disease severity in nonalcoholic steatohepatitis. J Hepatol 2015; 62: 405-411 [PMID: 25195551 DOI: 10.1016/j.jhep.2014.08.040]
92. Abramovitch S, Dahan-Bachar L, Sharvit E, Weisman Y, Ben Tov A, Brazowski E, Reif S. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut 2011; 60: 1728-1737 [PMID: 21816960 DOI: 10.1136/gut.2010.234666]
93. Marino L, Jornayvaz FR. Endocrine causes of nonalcoholic fatty liver disease. World J Gastroenterol 2015; 21: 11053-11076 [PMID: 26494962 DOI: 10.3748/wjg.v21.i39.11053]
94. Candia R, Riquelme A, Baudrand R, Carvajal CA, Morales M, Solís N, Pizarro M, Escalona A, Carrasco G, Boza C, Pérez G, Padilla O, Cerda J, Fardella CE, Arrese M. Overexpression of 11β-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue and portal hypercortisolism in non-alcoholic fatty liver disease. Liver Int 2012; 32: 392-399 [PMID: 22136330 DOI: 10.1111/j.1478-3231.2011.02685.x]
95. Tarantino G, Finelli C. Pathogenesis of hepatic steatosis: the link between hypercortisolism and non-alcoholic fatty liver disease. World J Gastroenterol 2013; 19: 6735-6743 [PMID: 24187449 DOI: 10.3748/wjg.v19.i40.6735]
96. de Silva HJ, Dassanayake AS. Non-alcoholic fatty liver disease: confronting the global epidemic requires better awareness. J Gastroenterol Hepatol 2009; 24: 1705-1707 [PMID: 20136955 DOI: 10.1111/j.1440-1746.2009.06026.x]